Tata India Pharma & Healthcare Fund Regular-Growth
The fund is rated 1 star. The investment selection within each asset type and balance between returns and downside risk provided some support. The investment selection within each industry was the main limitation and did not provide enough support for a higher rating. A higher annual fee of 2.37% was a minor drawback.
This fund has a ok track record with Asset Selection/Timing, a bad track record with Stock Selection/Timing. It is important to note, however, that this fund has a 1565.28 AUM and a 2.37 expense ratio. Considering all these factors, we have rated this fund as 1.0 star.
आमचा स्कोअर दीर्घकालीन कामगिरी, जोखीम आणि सातत्य यांचे वजन करतो — फक्त मागील परतावे नाही.
परतावा
8 Oct 2026 पर्यंत
जोखीम गुणोत्तरे
30 Sep 2026 पर्यंत
पोर्टफोलिओ
31 Aug 2026 पर्यंत
मार्केट-कॅप विभागणी
क्षेत्रनिहाय वाटप
होल्डिंग्स (42)
| होल्डिंग | फंडाचा % | मूल्य | शेअर्स |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 8.43% | ₹132.02 Cr | 6,65,178 |
| Healthcare Global Enterprises Ltd. | 6.30% | ₹98.56 Cr | 13,44,012 |
| Divi's Laboratories Ltd. | 5.65% | ₹88.49 Cr | 93,472 |
| Abbott India Ltd. | 5.44% | ₹85.11 Cr | 32,924 |
| Rainbow Children's Medicare Ltd. | 4.47% | ₹70.04 Cr | 4,95,081 |
| Apollo Hospitals Enterprise Ltd. | 4.32% | ₹67.64 Cr | 76,013 |
| Cipla Ltd. | 4.27% | ₹66.78 Cr | 4,73,861 |
| Dr. Reddy's Laboratories Ltd. | 4.21% | ₹65.84 Cr | 5,70,312 |
| Max Healthcare Institute Ltd. | 3.80% | ₹59.55 Cr | 5,71,483 |
| Fortis Healthcare Ltd. | 3.30% | ₹51.63 Cr | 5,69,351 |
फंड तपशील
Long Term Capital Appreciation. Investment in equity/equity related instruments of the companies in the Pharma & Healthcare sector in India.
The scheme seeks long term capital appreciation by investing atleast 80% of it's net assets in equity/equity related instruments of the companies in the pharma & healthcare sectors in India.
Exit load of 0.25% if redeemed within 30 days.